Amedisys, Inc. (NASDAQ:AMED – Get Free Report) has received an average rating of “Hold” from the eight research firms that are presently covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $97.50.
Several equities analysts have issued reports on the company. Cantor Fitzgerald reissued a “neutral” rating and issued a $101.00 price target on shares of Amedisys in a research note on Thursday, April 25th. Raymond James reissued a “market perform” rating on shares of Amedisys in a research note on Tuesday, March 26th. StockNews.com raised shares of Amedisys from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Royal Bank of Canada increased their price objective on shares of Amedisys from $97.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 25th.
View Our Latest Report on AMED
Hedge Funds Weigh In On Amedisys
Amedisys Stock Down 0.4 %
Shares of NASDAQ AMED opened at $92.08 on Friday. The company has a 50 day simple moving average of $92.40 and a 200 day simple moving average of $93.33. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.09 and a quick ratio of 1.09. Amedisys has a 1 year low of $73.10 and a 1 year high of $96.44. The firm has a market cap of $3.01 billion, a PE ratio of -143.88, a price-to-earnings-growth ratio of 3.42 and a beta of 0.84.
Amedisys (NASDAQ:AMED – Get Free Report) last announced its earnings results on Wednesday, April 24th. The health services provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. Amedisys had a positive return on equity of 12.85% and a negative net margin of 0.91%. The business had revenue of $571.41 million for the quarter, compared to analysts’ expectations of $565.38 million. During the same period in the prior year, the business posted $1.00 earnings per share. The firm’s revenue was up 2.7% on a year-over-year basis. On average, research analysts forecast that Amedisys will post 4.57 EPS for the current year.
About Amedisys
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
See Also
- Five stocks we like better than Amedisys
- CD Calculator: Certificate of Deposit Calculator
- Appleās Earnings Show Investors Its Strength and Its Weakness
- Bank Stocks – Best Bank Stocks to Invest In
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.